Central venous catheter-associated Leifsonia aquatica bacteremia in a hemodialysis-dependent patient
ABSTRACT Infections associated with Leifsonia aquatica are particularly uncommon. We describe a central venous catheter-associated L. aquatica bacteremia in a hemodialysis-dependent patient. A review of the literature revealed only 1 other case report involving 10 hemodialysis patients with documented L. aquatica bacteremia.
SourceAvailable from: jcm.asm.org[Show abstract] [Hide abstract]
ABSTRACT: Leifsonia aquatica is an aquatic bacterium that is typically found in environmental water habitats. Infections due to L. aquatica are rare, and commonly catheter-associated in immunocompromised patients. We report the first case of an acute septicemia caused by L. aquatica in a healthy immunocompetent host after cryopexy in the absence of catheter.Journal of clinical microbiology 08/2013; 51(11). DOI:10.1128/JCM.01339-13 · 4.23 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Abstract Background: Peritonitis has remained the most common serious complication of continuous ambulatory peritoneal dialysis (CAPD). In most cases, these infections are monomicrobial, and the pathogens involved most commonly are Staphylococci. Recently, polymicrobial infections with rare organisms have been reported more often. Case Report: We describe a patient who developed recurrent episodes of CAPD-associated peritonitis with a total of four pathogens: Methicillin-resistant S. aureus, Haemophilus parainfluenzae, Leifsonia aquatica, and Gordonia spp. The infection most likely was acquired when the patient used tap water for dialysis during a camping trip. All episodes were treated successfully with antibiotics. Finally, the device was removed, and later, a new catheter was implanted, which still is in use. Conclusion: Peritoneal dialysis-associated peritonitis may be caused by rare organisms. Antibiotics may be able to treat disease temporarily, but removal of contaminated catheters usually is required.Surgical Infections 12/2012; 13(6):409-12. DOI:10.1089/sur.2011.009 · 1.72 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Clinical microbiology laboratories have to accurately identify clinical microbes. However, some isolates are difficult to identify by the automated biochemical text platforms, which are called "difficult-to-identify" microbes in this study. Therefore, the ability of 16S ribosomal DNA (16S rDNA) and internal transcribed spacer 2 (ITS2) sequencing to identify these "difficult-to-identify" bacteria and fungi was assessed in this study. Samples obtained from a teaching hospital over the past three years were examined. The 16S rDNA of four standard strains, 18 clinical common isolates, and 47 "difficult-to-identify" clinical bacteria were amplified by PCR and sequenced. The ITS2 of eight standard strains and 31 "difficult-to-identify" clinical fungi were also amplified by PCR and sequenced. The sequences of 16S rDNA and ITS2 were compared to reference data available in GenBank by using the BLASTN program. These microbes were identified according to the percentage of similarity to reference sequences of strains in GenBank. The results from molecular sequencing methods correlated well with automated microbiological identification systems for common clinical isolates. Sequencing results of the standard strains were consistent with their known phenotype. Overall, 47 "difficult-to-identify" clinical bacteria were identified as 35 genera or species by sequence analysis (with 10 of these identified isolates first reported in clinical specimens in China and two first identified in the international literature). 31 "difficult-to-identify" clinical fungi tested could be identified as 15 genera or species by sequence analysis (with two of these first reported in China). Our results show the importance of 16S rDNA and internal ITS2 sequencing for the molecular identification of "difficult-to-identify" bacteria and fungi. The development of this method with advantages of convenience, availability, and cost-effectiveness will make it worth extending into clinical practice in developing countries.Annals of Clinical Microbiology and Antimicrobials 01/2014; 13(1):1. DOI:10.1186/1476-0711-13-1 · 1.51 Impact Factor